Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

OxyContin’s Abuse-Deterrent Claims Strong, But Stronger Claims Possible

Apr 22 2013

• By Cathy Dombrowski

Related Content

FDA’s Opioid To-Do List Could Redefine Pain Market For Brands, Generics

Feb 18 2013

Purdue Execs’ Exclusion Stands But Court Tells HHS To Justify 12-Year Term

Jul 28 2012

Purdue Execs Plead Guilty To Misbranding OxyContin; Company Pays $700 Mil.

May 14 2007

No Abuse-Resistance Claim For Endo’s Opana ER Reformulation

Dec 12 2011

Remoxy's "Complete Response" Letter Has No Clear Culprit But Many Suspects

Jun 24 2011

Opioid Abuse-Deterrent Labeling Claim Decision By FDA Could Come Soon

Apr 15 2013

Related Companies

Purdue Pharma L.P.

Pfizer Inc.

DURECT Corporation

Nektar Therapeutics

Zogenix, Inc.

Endo, Inc.

Additional Topics

United States Regulation BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window